Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : ARQT save search
Arcutis Appoints David Topper as Chief Financial Officer
Published: 2024-04-10 (Crawled : 12:00) - globenewswire.com
MS | News 0 d | $93.85 0.1% 0.0% 4.8M
|
Finance
|
| O: -1.43%
H: 0.0%
C: 0.0%
ARQT | $8.76 0.23% 0.23% 2M
|
Health Technology
|
| O: -6.11%
H: 5.83%
C: 4.73%
financial
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Published: 2024-04-05 (Crawled : 20:00) - globenewswire.com
ARQT | $8.76 0.23% 0.23% 2M
|
Health Technology
| Email alert
Add to watchlist
nasdaq grants
Sol-Gel’s Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® Cream
Published: 2024-04-01 (Crawled : 11:00) - globenewswire.com
SLGL | $0.92 -0.56% -0.57% 7.6K
|
Health Technology
|
| O: 2.03%
H: 4.0%
C: -0.49%
ARQT | $8.76 0.23% 0.23% 2M
|
Health Technology
|
| O: 3.16%
H: 0.0%
C: -2.81%
zoryve drug collaboration
Arcutis to Present at the 23rd Annual Needham Virtual Healthcare Conference
Published: 2024-03-28 (Crawled : 13:00) - arcutis.com
ARQT | $8.76 0.23% 0.23% 2M
|
Health Technology
|
| O: 0.68%
H: 0.0%
C: 0.0%
conference
Arcutis Promotes Todd Tucker to Chief Human Resources Officer
Published: 2024-03-11 (Crawled : 12:00) - globenewswire.com
ARQT | $8.76 0.23% 0.23% 2M
|
Health Technology
|
| O: 0.18%
H: 3.39%
C: -10.12%
Arcutis Presents Late-Breaking Data From INTEGUMENT-PED Phase 3 Trial of Roflumilast Cream 0.05% in Atopic Dermatitis in Children Ages 2 to 5 at the American Academy of Dermatology Annual Meeting
Published: 2024-03-10 (Crawled : 20:20) - globenewswire.com
ARQT | $8.76 0.23% 0.23% 2M
|
Health Technology
|
| O: 0.18%
H: 3.39%
C: -10.12%
children dermatitis meeting trial
New Research Reveals Genomic Profile of Seborrheic Dermatitis and Answers Key Questions on Immune Response and Skin Barrier Dysfunction
Published: 2024-03-09 (Crawled : 00:20) - arcutis.com
ARQT | $8.76 0.23% 0.23% 2M
|
Health Technology
| Email alert
Add to watchlist
genomic dermatitis research key skin response
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Published: 2024-03-05 (Crawled : 21:00) - globenewswire.com
ARQT | $8.76 0.23% 0.23% 2M
|
Health Technology
|
| O: 1.38%
H: 2.08%
C: -5.52%
nasdaq grants
Arcutis Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
Published: 2024-03-04 (Crawled : 21:00) - globenewswire.com
MS | News 0 d | $93.85 0.1% 0.0% 4.8M
|
Finance
|
| O: -0.94%
H: 2.19%
C: -0.07%
ARQT | $8.76 0.23% 0.23% 2M
|
Health Technology
|
| O: -1.37%
H: 2.5%
C: 0.93%
offering
Arcutis Announces Acceptance of Late Breaking Abstract in Atopic Dermatitis Among Five New Topical Roflumilast Data Being Presented at the American Academy of Dermatology Annual Meeting
Published: 2024-03-04 (Crawled : 14:00) - arcutis.com
ARQT | $8.76 0.23% 0.23% 2M
|
Health Technology
|
| O: 2.29%
H: 2.57%
C: -9.05%
dermatitis meeting
Arcutis to Present at the TD Cowen 44th Annual Health Care Conference
Published: 2024-02-29 (Crawled : 22:00) - globenewswire.com
ARQT | $8.76 0.23% 0.23% 2M
|
Health Technology
|
| O: -0.88%
H: 16.88%
C: 15.51%
conference health care
Arcutis Announces Pricing of $150 Million Public Offering
Published: 2024-02-29 (Crawled : 05:00) - arcutis.com
MS | News 0 d | $93.85 0.1% 0.0% 4.8M
|
Finance
|
| O: 0.51%
H: 0.17%
C: -0.52%
ARQT | $8.76 0.23% 0.23% 2M
|
Health Technology
|
| O: -8.84%
H: 11.38%
C: 8.32%
million offering
Arcutis Announces Proposed Public Offering
Published: 2024-02-28 (Crawled : 21:00) - globenewswire.com
MS | News 0 d | $93.85 0.1% 0.0% 4.8M
|
Finance
|
| O: 0.51%
H: 0.17%
C: -0.52%
ARQT | $8.76 0.23% 0.23% 2M
|
Health Technology
|
| O: -8.84%
H: 11.38%
C: 8.32%
offering
Arcutis and Sato Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in Japan
Published: 2024-02-28 (Crawled : 21:00) - globenewswire.com
ARQT | $8.76 0.23% 0.23% 2M
|
Health Technology
|
| O: -8.84%
H: 11.38%
C: 8.32%
japan collaboration agreement
Arcutis Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Published: 2024-02-27 (Crawled : 11:00) - arcutis.com
ARQT | $8.76 0.23% 0.23% 2M
|
Health Technology
|
| O: 8.36%
H: 7.9%
C: 1.24%
business year update financial results
Arcutis to Report Fourth Quarter and Full Year 2023 Financial Results
Published: 2024-02-16 (Crawled : 13:00) - globenewswire.com
ARQT | $8.76 0.23% 0.23% 2M
|
Health Technology
|
| O: 0.0%
H: 28.48%
C: 16.69%
report year financial results
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Published: 2024-02-06 (Crawled : 21:00) - globenewswire.com
ARQT | $8.76 0.23% 0.23% 2M
|
Health Technology
|
| O: -2.63%
H: 5.41%
C: 2.88%
nasdaq grants
Arcutis to Present at the Guggenheim Healthcare Talks – 6th Annual Biotechnology Conference
Published: 2024-01-31 (Crawled : 13:00) - globenewswire.com
ARQT | $8.76 0.23% 0.23% 2M
|
Health Technology
|
| O: -0.51%
H: 7.02%
C: 0.51%
conference
Journal of the American Academy of Dermatology Publishes ZORYVE (roflumilast) Foam, 0.3% Results for Seborrheic Dermatitis from Pivotal Phase 3 Trial
Published: 2024-01-29 (Crawled : 13:00) - globenewswire.com
ARQT | $8.76 0.23% 0.23% 2M
|
Health Technology
|
| O: 3.4%
H: 10.95%
C: 10.58%
dermatitis zoryve trial results
ZORYVE® (roflumilast) Topical Foam, 0.3%, for the Treatment of Seborrheic Dermatitis Launches in the United States
Published: 2024-01-22 (Crawled : 13:00) - globenewswire.com
ARQT | $8.76 0.23% 0.23% 2M
|
Health Technology
|
| O: 5.85%
H: 7.56%
C: 2.91%
zoryve dermatitis treatment
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.